Are androgenetic alopecia and hair thinning affecting your patients' confidence? In our Global Webinar Series, DermapenWorld’s Clinical Director, Dr Andrew Christie-Schwarz, explores how the era of regenerative medicine and biomimetic exosomes is transforming the way we revitalise the scalp for a vast patient demographic.
Androgen Receptor & Biomimetic Exosomes
In this episode's highlights, get key insights, including:
Pathophysiology and clinical aims for the treatment of androgenetic alopecia.
Diagnostic tools like the Norwood and Ludwig scales for male and female pattern baldness.
The role of biomimetic exosomes, polynucleotides, and growth factors in hair restoration.
In-clinic procedural techniques using Dermapen 4® and the Dp Dermaceuticals MG-EXO-GROW™ collection.
Essential home care protocols and real-world patient case studies.
Explore More Expert Strategies
The Role of Biomimetic Exosomes in Modern Hair Restoration Protocols
Want to take a deep dive into the topic? Read the information below for more
DermapenWorld recently hosted an exclusive webinar featuring our Clinical Director and Global Medical Trainer, Dr Andrew Christie-Schwarz. With 25 years of expertise in skin needling, Dr Christie-Schwarz explored the complex pathophysiology of hair loss and the revolutionary role of biomimetic exosome technology. The session highlighted that androgenetic alopecia is a progressive condition requiring a multifactorial approach that moves beyond traditional "lotions and potions" toward evidence-based regenerative medicine.
By embracing the Synergy of Solutions, Professional Partners can focus on revitalising dormant follicles and blocking the hormonal triggers of hair thinning. Dr Christie-Schwarz confirms that integrating advanced clinical protocols with targeted home care is the key to restoring hair density and patient confidence.
Vascular Activation: A Dermapen Treatment™ helps promote angiogenesis and vasodilation, creating a "fertile" environment by increasing blood flow and nutrient delivery to the follicle.
Follicular Maximisation: By improving the transport of growth factors and amino acids, microneedling assists in follicular maximisation, helping transition vellus hair into terminal hair.
Precision Targeting: For hair restoration, professionals should target the intradermal layer rather than the deeper subcutaneous tissue to avoid excessive inflammation that may distract from the regenerative process.
Controlled Healing: The Dermapen 4® facilitates a controlled wound-healing response that typically resolves within 10–14 days, allowing for frequent, cumulative treatments every 2 weeks.
Visual Endpoints: Success is reproducible by achieving consistent pinpoint blood during the procedure, typically requiring needle depths between 0.5mm and 1.25mm.
Dr Andrew Christie-Schwarz addressed the limitations of conventional hair loss treatments, detailing why precision is essential for managing androgenetic alopecia. He emphasised that successful restoration requires a biological "reset" of the hair growth cycle:
Prolonging Anagen Phase: Effective protocols have been shown to prolong the anagen (growth) phase of hair, which can last between 2 and 7 years, ensuring greater hair longevity.
Hormonal Modulation: Androgenetic alopecia involves the over-conversion of dihydrotestosterone (DHT) in scalp cells, leading to follicular minimisation. Precision delivery of active ingredients can now help block this process locally.
Pre-Surgical Priming: For patients considering hair transplantation, performing 2–3 Dermapen Treatments™ beforehand increases vascularity, making the scalp more receptive to the transplant.
A pivotal shift in hair restoration is the integration of synthesised, biomimetic exosome technology. Dr Christie-Schwarz presented how the Dp Dermaceuticals EXO-GROW™ range is redefining what is possible in regenerative aesthetics.
Cellular Ambassadors: Exosomes are nano-sized vesicles that act as powerful messengers, carrying a rich cargo of Growth Factors and Polynucleotides essential for cell-to-cell communication.
Homogeneity and Recognition: Unlike plant or animal extracts, DermapenWorld’s biomimetic formulations use a "human sequence" that the body recognises, ensuring that repair messages are accepted rather than rejected.
DHT Blocking: The key innovation is a laboratory-synthesised Androgen Receptor combined with Stem Cell Factor and PDRN, which provides a non-prescription solution to block localised DHT over-conversion.
The integration of Dp Dermaceuticals EXO-GROW™ into alopecia protocols provides a sophisticated approach to healing that goes beyond traditional topicals.
Potentiating Results: This technology has been shown to deliver up to 160% greater efficacy than standard 5% Minoxidil solutions in promoting thicker, more voluminous hair.
Synergistic Formulation: Each vial contains 17 Amino Acids, 12 Growth Factors, and 3% Sodium DNA (PDRN) to regulate keratinisation and support the scalp's structural integrity.
Essential Daily Care: The Dp Dermaceuticals EXO-GROW TONIC™ ensures consistent exposure to regenerative signals between clinic visits, targeting common scalp concerns such as dandruff and irritation, as well as Hair Loss.
Transform your practice with DermapenWorld
Dermapen Treatments™ with Dermapen 4 and Dp Dermaceuticals EXO-GROW™ provide a powerful, integrative approach to managing androgenetic alopecia. By shifting focus toward regenerative medicine, you empower your clients' skin to revitalise itself from the inside out, delivering safe, effective, and life-changing results. This evidence-based technology is a vital addition to any clinical practice, allowing you to confidently manage some of the most challenging Hair concerns in aesthetic medicine.
